IN2012DN00754A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00754A IN2012DN00754A IN754DEN2012A IN2012DN00754A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A IN 754DEN2012 A IN754DEN2012 A IN 754DEN2012A IN 2012DN00754 A IN2012DN00754 A IN 2012DN00754A
- Authority
- IN
- India
- Prior art keywords
- compounds
- antagonists
- lpa
- medicaments
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23128209P | 2009-08-04 | 2009-08-04 | |
| PCT/US2010/044284 WO2011017350A2 (fr) | 2009-08-04 | 2010-08-03 | Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00754A true IN2012DN00754A (fr) | 2015-06-19 |
Family
ID=43544907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN754DEN2012 IN2012DN00754A (fr) | 2009-08-04 | 2010-08-03 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8592402B2 (fr) |
| EP (1) | EP2462128B1 (fr) |
| JP (1) | JP2013501064A (fr) |
| CN (1) | CN102574822A (fr) |
| IN (1) | IN2012DN00754A (fr) |
| WO (1) | WO2011017350A2 (fr) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010068775A2 (fr) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| IN2012DN00754A (fr) | 2009-08-04 | 2015-06-19 | Amira Pharmaceuticals Inc | |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| PH12013501136A1 (en) | 2010-12-07 | 2013-07-08 | Amira Pharmaceuticals Inc | Lysophosphatidic acid receptor antagonists and uses thereof |
| CN103596947A (zh) | 2011-04-05 | 2014-02-19 | 艾米拉医药股份有限公司 | 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物 |
| WO2012138648A1 (fr) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions et procédés pour la modulation de récepteurs au lpa |
| US8912202B2 (en) * | 2011-08-08 | 2014-12-16 | Merck Patent Gmbh | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists |
| AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| EP2783016A1 (fr) | 2011-11-22 | 2014-10-01 | Intermune, Inc. | Procédés de diagnostic et de traitement de la fibrose pulmonaire idiopathique |
| HRP20161774T1 (hr) | 2012-06-13 | 2017-02-24 | F. Hoffmann - La Roche Ag | Novi diazaspirocikloalkan i azaspirocikloalkan |
| EA201492283A1 (ru) * | 2012-06-20 | 2015-04-30 | Ф. Хоффманн-Ля Рош Аг | Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) |
| WO2014026039A2 (fr) * | 2012-08-09 | 2014-02-13 | Neuropore Therapies, Inc. | Dérivés de benzène substitués par un aryle et hétéroaryle à titre de modulateurs des voies de signalisation de la pi-3 kinase |
| BR112015004111A2 (pt) | 2012-09-25 | 2017-07-04 | Hoffmann La Roche | novos derivados bicíclicos |
| ES2667798T3 (es) | 2012-12-28 | 2018-05-14 | Ube Industries, Ltd. | Compuesto heterocíclico sustituido con halógeno |
| US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US10000459B2 (en) * | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| EA038294B1 (ru) * | 2013-05-24 | 2021-08-05 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
| GB201314926D0 (en) | 2013-08-20 | 2013-10-02 | Takeda Pharmaceutical | Novel Compounds |
| KR20160087900A (ko) | 2013-11-26 | 2016-07-22 | 에프. 호프만-라 로슈 아게 | 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일 |
| SI3122750T1 (sl) | 2014-03-26 | 2019-12-31 | F. Hoffmann-La Roche Ag | Biciklične spojine kot zaviralci proizvodnje avtotaksina (ATX) in lizofosfatidne kisline (LPA) |
| KR20160128428A (ko) | 2014-03-26 | 2016-11-07 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 |
| SG11201607920RA (en) | 2014-04-04 | 2016-10-28 | X Rx Inc | Substituted spirocyclic inhibitors of autotaxin |
| WO2015175171A1 (fr) * | 2014-04-23 | 2015-11-19 | X-Rx Discovery, Inc. | N-(2-amino)-2-oxoétriylbenzamides substitués en tant qu'inhibiteurs d'autotaxine |
| AU2015281021B9 (en) | 2014-06-27 | 2019-03-28 | Ube Corporation | Salt of halogen-substituted heterocyclic compound |
| WO2016046782A1 (fr) * | 2014-09-26 | 2016-03-31 | Glenmark Pharmaceuticals S.A. | Composés imidazole biaryle en tant qu'inhibiteurs de la s-nitrosoglutathion réductase |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| AU2016258837B2 (en) | 2015-05-01 | 2020-12-03 | Onl Therapeutics, Inc. | Peptide compositions and methods of use |
| HK1252425A1 (zh) | 2015-06-05 | 2019-05-24 | Vertex Pharmaceuticals Incorporated | 用於治疗脱髓鞘疾病的三唑类药物 |
| JP6886967B2 (ja) | 2015-09-04 | 2021-06-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | フェノキシメチル誘導体 |
| RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
| JP6877413B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| CN107635995B (zh) | 2015-09-24 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 作为atx抑制剂的二环化合物 |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| WO2018106643A1 (fr) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Azoles hétérocycliques pour le traitement de maladies de démyélinisation |
| WO2018106641A1 (fr) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles pour le traitement de maladies démyélinisantes |
| WO2018106646A1 (fr) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles pour traiter des maladies démyélinisantes |
| WO2018167113A1 (fr) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | Nouveaux composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| EP3596059B1 (fr) | 2017-03-16 | 2024-04-24 | F. Hoffmann-La Roche AG | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca |
| AU2018359224B2 (en) | 2017-10-30 | 2023-10-05 | Neuropore Therapies, Inc. | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
| CN112074515B (zh) * | 2017-12-19 | 2025-01-10 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| JP7202383B2 (ja) * | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
| US10662172B2 (en) | 2017-12-19 | 2020-05-26 | Bristol-Myers Squibb Company | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| KR102698386B1 (ko) | 2017-12-19 | 2024-08-22 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산 |
| EP3728210B1 (fr) * | 2017-12-19 | 2026-02-11 | Bristol-Myers Squibb Company | Acides carbamoyle cyclohexyliques à liaison n isoxazole utilisés en tant qu'antagonistes de lpa |
| JP7526096B2 (ja) * | 2017-12-19 | 2024-07-31 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン |
| KR20200100713A (ko) * | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸 |
| WO2019126103A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Acides pyrazoles azoles cyclohexyliques utilisés en tant qu'antagonistes de lpa |
| KR102697358B1 (ko) * | 2017-12-19 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 |
| TW202017918A (zh) | 2017-12-19 | 2020-05-16 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之環己基酸三唑吖 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN113366000A (zh) | 2018-09-18 | 2021-09-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的氧杂双环酸 |
| EP3986552B1 (fr) | 2019-06-18 | 2024-09-18 | Bristol-Myers Squibb Company | Acides carboxyliques isoxazole en tant qu'antagonistes de lpa |
| US12466804B2 (en) | 2019-06-18 | 2025-11-11 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as LPA antagonists |
| ES3054967T3 (en) * | 2019-06-18 | 2026-02-09 | Bristol Myers Squibb Co | Triazole carboxylic acids as lpa antagonists |
| NZ784711A (en) | 2019-07-30 | 2025-11-28 | Taisho Pharmaceutical Co Ltd | Urea compound for antagonizing lpa1 receptor |
| EP4058144A1 (fr) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Pyridylsulfonamides de carbamate de triazole utilisées en tant qu'antagonistes du récepteur de lpa et leurs utilisations |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR102913125B1 (ko) | 2020-06-03 | 2026-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| WO2022013378A1 (fr) * | 2020-07-16 | 2022-01-20 | Chiesi Farmaceutici S.P.A. | Dérivés amido d'acide cyclohexane utilisés en tant qu'inhibiteurs des récepteurs de lpa |
| CA3218917A1 (fr) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Antagonistes du recepteur lpa et leurs utilisations |
| WO2022241023A1 (fr) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Antagonistes du récepteur lpa et leurs utilisations |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
| US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| JPH0778017B2 (ja) | 1985-12-28 | 1995-08-23 | 住友製薬株式会社 | パルス的かつ持続放出性製剤 |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| CA2276034A1 (fr) | 1996-12-23 | 1998-07-02 | Mimi Lifen Quan | Oxygene ou soufre contanant des hetero-aromatiques utilises comme inhibiteurs du facteur xa |
| JP3237608B2 (ja) | 1997-04-21 | 2001-12-10 | 住友製薬株式会社 | イソキサゾール誘導体 |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
| AU4327600A (en) | 1999-04-02 | 2000-10-23 | Du Pont Pharmaceuticals Company | Aryl sulfonyls as factor xa inhibitors |
| ATE420878T1 (de) | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
| US7521192B2 (en) | 2001-04-18 | 2009-04-21 | Rigel Pharmaceuticals, Inc. | EDG: modulators of lymphocyte activation and migration |
| ATE406915T1 (de) | 2001-07-17 | 2008-09-15 | Ono Pharmaceutical Co | Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| AU2002367129A1 (en) | 2001-12-25 | 2003-07-15 | Ajinomoto Co., Inc. | Organ fibrosis inhibitors |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
| US20050101518A1 (en) | 2002-01-18 | 2005-05-12 | David Solow-Cordero | Methods of treating conditions associated with an EDG-2 receptor |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Ｅｄｇ受容体に関連する症状の処置方法 |
| WO2003094965A2 (fr) | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation de cellules souches neurales et de cellules progenitrices neurales |
| CA2484233A1 (fr) | 2002-05-13 | 2003-11-27 | Eli Lilly And Company | Composes multicycliques que l'on utilise comme antagonistes de l'hormone de concentration de melanine dans le traitement de l'obesite et du diabete |
| JP4596314B2 (ja) | 2002-05-28 | 2010-12-08 | 小野薬品工業株式会社 | β−アラニン誘導体およびその用途 |
| WO2004002530A1 (fr) | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | Remede pour maladie chronique |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| CA2506243A1 (fr) | 2002-11-19 | 2004-06-03 | Amgen Inc. | Genes amplifies impliques dans un cancer |
| US20040167132A1 (en) | 2003-01-16 | 2004-08-26 | Geetha Shankar | Methods of treating conditions associted with an Edg-2 receptor |
| US20040192739A1 (en) | 2003-01-16 | 2004-09-30 | David Solow-Cordero | Methods of treating conditions associated with an Edg-2 receptor |
| US20050065194A1 (en) | 2003-01-16 | 2005-03-24 | Geetha Shankar | Methods of treating conditions associated with an Edg-2 receptor |
| US7135469B2 (en) | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
| WO2004099164A1 (fr) | 2003-05-02 | 2004-11-18 | Rigel Pharmaceuticals, Inc. | Diphenyl isoxazoles, pyrazoles et oxadiazoles substitues, destines au traitement d'une infection par le vhc |
| EP1638551B1 (fr) | 2003-05-19 | 2011-12-21 | Irm Llc | Composes immunosuppresseurs et compositions |
| WO2007016784A1 (fr) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Nouveau 1,2,3-tπazolylméthyle-benzothiophène substitués ou -indole et leur utilisation en tant qu’inhibiteurs de biosynthèse leukotπène |
| WO2005012269A1 (fr) * | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | Nouveau compose azole |
| US7875745B2 (en) | 2003-12-19 | 2011-01-25 | Ono Pharmaceutical Co., Ltd. | Compounds having lysophosphatidic acid receptor antagonism and uses thereof |
| DE10360369A1 (de) | 2003-12-22 | 2005-07-14 | Bayer Cropscience Ag | Amide |
| JP2006096712A (ja) | 2004-09-30 | 2006-04-13 | Senju Pharmaceut Co Ltd | Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤 |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| EP1893591A1 (fr) | 2005-06-08 | 2008-03-05 | Novartis AG | Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p |
| WO2007007588A1 (fr) | 2005-07-08 | 2007-01-18 | Ono Pharmaceutical Co., Ltd. | Compose comportant un groupe cyclique ayant un noyau plan |
| CA2619101A1 (fr) | 2005-08-23 | 2007-03-01 | Irm Llc | Composes immunosuppresseurs et compositions associees |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| MX2008009475A (es) | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
| CA2643670A1 (fr) | 2006-02-27 | 2007-08-30 | Sterix Limited | Compose |
| US20090029949A1 (en) | 2006-05-25 | 2009-01-29 | Parrill-Baker Abby L | GPCR Ligands Identified by Computational Modeling |
| WO2008024979A2 (fr) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Procédés d'utilisation de lysophospholipides de signalisation cellulaire |
| US20080051372A1 (en) | 2006-08-24 | 2008-02-28 | The Scripps Research Institute | Methods utilizing cell-signaling lysophospholipids |
| WO2008112201A2 (fr) | 2007-03-12 | 2008-09-18 | The General Hospital Corporation | Récepteur d'acide lysophosphatidique ciblant une maladie pulmonaire |
| US9163091B2 (en) | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| WO2009011850A2 (fr) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
| CN105418450A (zh) | 2008-05-05 | 2016-03-23 | 赛诺菲-安万特 | 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途 |
| WO2010068775A2 (fr) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| IN2012DN00754A (fr) | 2009-08-04 | 2015-06-19 | Amira Pharmaceuticals Inc | |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
-
2010
- 2010-08-03 IN IN754DEN2012 patent/IN2012DN00754A/en unknown
- 2010-08-03 US US13/388,502 patent/US8592402B2/en active Active
- 2010-08-03 WO PCT/US2010/044284 patent/WO2011017350A2/fr not_active Ceased
- 2010-08-03 EP EP10807045.9A patent/EP2462128B1/fr not_active Not-in-force
- 2010-08-03 CN CN2010800429638A patent/CN102574822A/zh active Pending
- 2010-08-03 JP JP2012523709A patent/JP2013501064A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2462128A4 (fr) | 2012-10-03 |
| WO2011017350A3 (fr) | 2011-06-30 |
| JP2013501064A (ja) | 2013-01-10 |
| EP2462128A2 (fr) | 2012-06-13 |
| CN102574822A (zh) | 2012-07-11 |
| EP2462128B1 (fr) | 2016-09-21 |
| WO2011017350A2 (fr) | 2011-02-10 |
| US8592402B2 (en) | 2013-11-26 |
| US20120196839A1 (en) | 2012-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02735A (fr) | ||
| IN2012DN02702A (fr) | ||
| IN2012DN00754A (fr) | ||
| PH12013501136A1 (en) | Lysophosphatidic acid receptor antagonists and uses thereof | |
| MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
| WO2010077883A3 (fr) | Antagonistes des récepteurs d'acide lysophosphatidique | |
| PH12020550450A1 (en) | Certain chemical entities, compositions and methods | |
| PH12015501737A1 (en) | Androgen receptor modulators and uses thereof | |
| PH12013500481A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12012502419A1 (en) | Estrogen receptor modulators and uses thereof | |
| WO2010068775A3 (fr) | Antagonistes d'alcyne de récepteurs d'acide lysophosphatidique | |
| PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| WO2012024620A3 (fr) | Inhibiteurs de l'autotaxine et leurs utilisations | |
| UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
| IN2012DN02471A (fr) | ||
| TN2010000463A1 (en) | Compositions and methods for preparing and using same |